NCT07341191 2026-02-12
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07393555 2026-02-06
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Not yet recruiting
NCT05797662 2026-01-23
A Study of Propranolol to Treat Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 2 Not yet recruiting
NCT07203053 2026-01-22
START-lung
ETOP IBCSG Partners Foundation
Phase 2 Not yet recruiting
NCT06858501 2025-12-31
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
Children's Oncology Group
Phase 2 Not yet recruiting
NCT07085728 2025-08-22
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT07107529 2025-08-12
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Not yet recruiting
NCT07040280 2025-06-27
Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT06783348 2025-01-23
RENALUT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT06310369 2024-07-22
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT06368414 2024-04-16
AsterA
Korean Society of Hematology
Phase 2 Not yet recruiting